.Pharmacolibrary.Drugs.ATC.A.A04AD10 .Pharmacolibrary.Drugs.ATC.A.A04AD10| name: | Dronabinol |
| ATC code: | A04AD10 | route: | oral |
| n-compartments | 2 |
Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), the principal psychoactive constituent of cannabis. It is used primarily as an antiemetic in the treatment of chemotherapy-induced nausea and vomiting and as an appetite stimulant in AIDS-related anorexia. Dronabinol is approved for these uses in several countries including the United States.
Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), single oral administration.
Hansen, JS, et al., & Svendsen, KB (2024). Pharmacokinetics and pharmacodynamics of cannabis-based medicine in a patient population included in a randomized, placebo-controlled, clinical trial. Clinical and translational science 17(1) e13685–None. DOI:10.1111/cts.13685 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38054364
Heuberger, JA, et al., & Freijer, J (2015). Population pharmacokinetic model of THC integrates oral, intravenous, and pulmonary dosing and characterizes short- and long-term pharmacokinetics. Clinical pharmacokinetics 54(2) 209–219. DOI:10.1007/s40262-014-0195-5 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25316574
Ahmed, AI, et al., & Kramers, C (2014). Safety and pharmacokinetics of oral delta-9-tetrahydrocannabinol in healthy older subjects: a randomized controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 24(9) 1475–1482. DOI:10.1016/j.euroneuro.2014.06.007 PUBMED:https://pubmed.ncbi.nlm.nih.gov/25035121